Merck MRK stock has declined 7.8% in the past month — in roughly the span after it announced fourth-quarter 2024 results and ...

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

AstraZeneca signed a $1.92 billion deal with China’s CSPC Pharmaceutical Group last year to develop cardiovascular medication ...

Silence’s execs will presumably be adjusting their plans to the fact that they can no longer hope for up to $1.3 billion in biobucks to come their way from a deal with Hansoh. The Chinese ...

Also, Viking was seen by some as a potential acquisition target for Merck. However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and ...

Merck is one of the largest pharmaceutical companies ... HS-10535, with China-based Hansoh Pharma. It signed a similar licensing deal with LaNova Medicines for the development of LM-299, a ...

AstraZeneca signed a $1.92 billion deal with China’s CSPC Pharmaceutical Group last year to develop cardiovascular medication, and Merck has a $2 billion agreement with China’s Hansoh ...

Merck reported adjusted earnings of $1.72 per ... a charge of 23 cents related to M&A deals with LaNova Medicines and Hansoh Pharma. Revenues rose 7% year over year (9% excluding Fx) to $15. ...